Comparison of the effects of denosumab with either active vitamin D or native vitamin D on bone mineral density and bone turnover markers in postmenopausal osteoporosis-Reference-Cited by-同舟云学术

Comparison of the effects of denosumab with either active vitamin D or native vitamin D on bone mineral density and bone turnover markers in postmenopausal osteoporosis

Published:2017-04-11 Issue:2 Volume:28 Page:376-379
ISSN:1439-7595
Container-title:Modern Rheumatology
language:en
Short-container-title:Modern Rheumatology

Author:

Suzuki Takako¹,Nakamura Yukio¹,Tanaka Mizue²,Kamimura Mikio³,Ikegami Shota¹,Uchiyama Shigeharu¹,Kato Hiroyuki¹

Affiliation:

1. Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Nagano, Japan;

2. Department of Orthopedic Surgery, Kawakita General Hospital, Tokyo, Japan;

3. Center of Osteoporosis and Spinal Disorders, Kamimura Orthopaedic Clinic, Matsumoto, Nagano, Japan

Publisher

Oxford University Press (OUP)

Subject

Rheumatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14397595.2017.1308454

Reference8 articles.

1. Denosumab in Postmenopausal Women with Low Bone Mineral Density

2. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years

3. Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients

4. A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures — A randomized, active comparator, double-blind study

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis;Osteoporosis International;2022-12-31

2. Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: A randomized clinical pilot study;Modern Rheumatology;2022-06-11

3. Two-year effectiveness of zoledronic acid with or without eldecalcitol in Japanese patients with osteoporosis: A randomized prospective study;Osteoporosis and Sarcopenia;2022-06

4. Overview of the clinical efficacy and safety of eldecalcitol for the treatment of osteoporosis;Archives of Osteoporosis;2022-05-05

5. Long-term safety of eldecalcitol in Japanese patients with osteoporosis: a retrospective, large-scale database study;Journal of Bone and Mineral Metabolism;2022-01-18